Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals,

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Asso

Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock m

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Mond

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $12

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating th

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

•   Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net R

RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today

Howard Marks hunts dislocation. His latest Oaktree 13F reveals five common-stock equity positions th

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to c

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year

Long-acting injectable adoption remains low, but Indivior's market position, payer access and consum

Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable mark

Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251205-1480992/1480992_decembe

Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the co

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin